Novo Nordisk A/S Share Price SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT
Equities
NOVOB
DK0060102614
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- DKK | - |
|
04:12pm | NOVO NORDISK : Jefferies reiterates its Sell rating | ZD |
12:37pm | What other health conditions are weight-loss drugs being tested for? | RE |
Sales 2024 * | 291B 41.93B 3,497B | Sales 2025 * | 352B 50.65B 4,224B | Capitalization | 4,382B 631B 52,619B |
---|---|---|---|---|---|
Net income 2024 * | 105B 15.07B 1,257B | Net income 2025 * | 128B 18.39B 1,534B | EV / Sales 2024 * | 15.1 x |
Net Debt 2024 * | 22.09B 3.18B 265B | Net cash position 2025 * | 6.04B 869M 72.48B | EV / Sales 2025 * | 12.4 x |
P/E ratio 2024 * |
42.3
x | P/E ratio 2025 * |
34.6
x | Employees | - |
Yield 2024 * |
1.2% | Yield 2025 * |
1.47% | Free-Float | 70.17% |
Latest transcript on Novo Nordisk A/S
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 01/91/01 | |
Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 19/15/19 |
Helge Lund
CHM | Chairman | 61 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
1st Jan change | Capi. | |
---|---|---|
+52.68% | 796B | |
-5.04% | 358B | |
+20.87% | 331B | |
+11.58% | 301B | |
+17.85% | 244B | |
+4.25% | 228B | |
+13.16% | 214B | |
+8.48% | 165B | |
-3.23% | 157B |
- Stock Market
- Equities
- NOVO B Stock
- NOVOB Stock